MedTrace Logo

Atezolizumab Plus Bevacizumab With HCC and HBV Infection

NCT04180072 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-04-09

No results posted yet for this study

Summary

This is a single-arm clinical trial. The main objective is to determine the efficacy of atezolizumab+bevacizumab therapy in patients with advanced hepatocellular carcinoma and with chronic hepatitis B virus infection. All eligible patients will receive atezolizumab + bevacizumab therapy.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

Atezolizumab

Atezolizumab 1200 mg IV on day 1 every 3 weeks

DRUG

Bevacizumab

Bevacizumab 15 mg/kg IV on day 1 every 3 weeks

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • Taipei Veterans General Hospital, Taiwan

    collaborator OTHER_GOV

  • Mackay Memorial Hospital

    collaborator OTHER

  • Changhua Christian Hospital

    collaborator OTHER

  • China Medical University Hospital

    collaborator OTHER

  • National Cheng-Kung University Hospital

    collaborator OTHER

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    collaborator OTHER

  • Taichung Veterans General Hospital

    collaborator OTHER

  • National Health Research Institutes, Taiwan

    lead OTHER

Principal Investigators

  • Chiun Hsu, PhD · National Taiwan University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-12
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04180072 on ClinicalTrials.gov